Longevity Health Holdings (XAGE) shares surged about 70% in extended trading Wednesday after the Nasdaq Hearings Panel granted its request to continue its listing.
Longevity said the decision followed a review of its business developments, financial disclosures, and proposed merger with 20/20 BioLabs on or before Sept. 2.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。